News for Kyowa Kirin Co., Ltd. (4151.T)

Amgen Inc (AMGN) and Kyowa Kirin Co., Ltd. have released new results from their ROCKET Phase 3 clinical trial program, evaluating rocatinlimab, a T-cell rebalan

**media[560114]**

PR NewswireTHOUSAND OAKS, Calif., March 4, 2025 THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of

PR NewswireTHOUSAND OAKS, Calif., March 1, 2025 Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in

”“ KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint ”“ ”“ Alignment reached with FDA and EMA on key aspects of the KOMET-017

**media[551505]**

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

**media[533438,533439]**

”“ Mollie Leoni, M.D. promoted to Chief Medical Officer ”“ ”“ Francis Burrows, Ph.D. promoted to Chief Scientific Officer ”“ ”“ Stephen Dale, M.D., steps

**media[507420]**

— Collaboration leverages Cimeio’s novel epitope shielding and immunotherapy discovery expertise — — Collaboration leverages Cimeio’s novel epitope shielding and i…

**media[486999,487000]**

”“ Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 ”“ ”“ 100% of 1L

PR NewswireTHOUSAND OAKS, Calif., Dec. 7, 2024 Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%THOUSAND OAKS, Calif., Dec. 7, 20

BLINCYTO ® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

PR NewswireTHOUSAND OAKS, Calif., Dec. 5, 2024 Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M CommitmentTHOUSAND OAKS,

PR NewswireTHOUSAND OAKS, Calif., Dec. 2, 2024 THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global H

Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH SAN DIEGO, Dec. 02, 2024 (GLO